| abstract |
A medical agent capable of effective cardioprotection when the symptoms of hypertension, cardiomegaly, myocardial infarction, arteriosclerosis, diabetic or non-diabetic kidney diseases, arhythmia accompanying re-stenosis, etc. after PTCA operation, cardiofibrosis and cardiac failure are concerned about. In particular, a medical agent comprising an effective amount of at least one protease inhibitor, intravenously or orally administered. The protease inhibitor is preferably a serine protease inhibitor which is specifically a chymotrypsin-like serine protease inhibitor. For example, use is made of a chymase inhibitor, viz. a peptide derivative of aryl diester of α-aminoalkylphosphonic acid represented by Suc-Val-Pro-PheP(OPh)2, preferably its enantiomer Suc-Val-Pro-L-PheP(OPh)2. |